- Home
- MRKR vs IBIO Comparison
MRKR vs IBIO Comparison
Compare MRKR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRKR | IBIO |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 50.4M |
| IPO Year | 2010 | 2009 |
Fundamental Metrics
Financial Performance| Metric | MRKR | IBIO |
|---|---|---|
| Price | $1.33 | $2.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.25 | $4.75 |
| AVG Volume (30 Days) | 123.0K | ★ 982.0K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.56 |
| 52 Week High | $4.07 | $5.31 |
Technical Indicators
Market Signals| Indicator | MRKR | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 49.09 |
| Support Level | $0.83 | $2.02 |
| Resistance Level | $1.44 | $3.01 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 5.65 | 16.25 |
Price Performance
Historical ComparisonAbout MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.